Adagio Medical Holdings (ADGM) risk factors, FY2024 10-K

Risks Related to Our Business

1. 01We are a medical device company that has incurred net losses in every period to date and expect to continue to incur significant losses as we develop our business, and our financial conditions raise substantial doubt about our ability to continue as a going concern
2. 02We may not be able to successfully execute our new business strategy and strategic restructuring
3. 03Changes in our business strategy or restructuring of our businesses may increase our costs or otherwise affect the profitability of our businesses or the value of our assets
4. 04Our growth and revenue prospects partially depend on our ability to accelerate the commercialization of our products and to capitalize on market opportunities
5. 05Our operating results may fluctuate significantly in the future, which makes our future operating results difficult to predict and could cause our operating results to fall below expectations or any guidance we may provide
6. 06Because our quarterly and annual results may fluctuate, period-to-period comparisons may not be the best indication of the underlying results of our business and should only be relied upon as one factor in determining how our business is performing
7. 07There is no assurance that we will be able to execute on our business model, including achieving market acceptance of our products
8. 08If we are unable to execute our business model, or if our business model does not drive the growth that we anticipate, or if our market opportunity is not as large as we have estimated, it could adversely affect our business and our prospects
9. 09We may need to raise additional capital to fund our development and commercialization plans
10. 10The size of the markets for our products may be smaller than estimated, limiting our ability to successfully sell our products
11. 11If we experience a significant disruption in our information technology systems or security incidents, our business could be adversely affected, including our ability to operate, the loss of confidential and proprietary information, increased remediation costs, and reputational damage
12. 12We may be unable to manage our anticipated growth effectively
13. 13We may acquire other companies or technologies, or form strategic partnerships with other companies, which could divert our management’s attention, increase our capital requirements, and otherwise disrupt our operations, subject us to other risks and harm our operating results
14. 14If we are unable to recruit and retain key executives and scientists, we may be unable to achieve our goals
15. 15Consolidation in the medical device industry could have an adverse effect on our revenue and results of operations
16. 16Unfavorable U.S. or global economic conditions as a result of a pandemic, political instability, natural disasters, or otherwise, could adversely affect our ability to raise capital and our business, financial condition and results of operations
17. 17If we fail to maintain an effective system of internal control over financial reporting, we may not be able to accurately report our financial results in a timely manner or prevent fraud, which could harm our business
18. 18We are not in compliance with Nasdaq’s audit committee requirements, and as a result our common stock may be delisted, which could have a material adverse effect on the liquidity of our common stock
19. 19If our facilities become unavailable or inoperable, our research and development program and commercialization launch plan could be adversely affected, which could materially and adversely impact our business, financial condition and results of operations
20. 20We use hazardous chemicals and biological materials in our business. Any claims relating to improper handling, storage or disposal of these materials could be time consuming and costly

Risks Related to our Products

1. 21If our clinical trials are unsuccessful or significantly delayed, or if we do not complete our clinical trials, our business may be harmed
2. 22We may not be successful in the commercialization of our products if we fail to establish relationships and successfully collaborate with leading life science companies and research institutions
3. 23If we are unable to establish an effective network for commercialization, including effective distribution channels and sales and marketing functions, it may adversely affect our business, financial condition, results of operations, and prospects
4. 24Our products may not be successful if there are inadequate physician training, practice and patient selection
5. 25The life sciences industry is highly competitive. Even if our products are commercialized and achieve broad scientific and market acceptance, if we fail to improve them or introduce compelling new products, our revenue and our prospects could be harmed
6. 26If we are unable to establish manufacturing capacity by ourselves or with third-party partners in a timely and cost-effective manner, commercialization of our products would be delayed, which would result in lost revenue and harm our business
7. 27Our products could have unknown defects or errors, which may give rise to claims against us and adversely affect market adoption of our products

Risks Related to Our Intellectual Property

1. 28The U.S. law relating to the patentability of certain inventions in the life sciences technology industry is uncertain and rapidly changing, which may adversely impact our existing patents or our ability to obtain patents in the future
2. 29Filing, prosecuting, maintaining, and defending patents on our products in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States can be less extensive than those in the United States
3. 30In addition, if we resort to legal proceedings to enforce our intellectual property rights or to determine the validity, scope and coverage of the intellectual property or other proprietary rights of others, the proceedings could be burdensome and expensive, even if we were to prevail
4. 31Issued patents covering our products could be found invalid or unenforceable if challenged, and could materially impact our business
5. 32If we are unable to protect the confidentiality of our trade secrets, the value of our technology could be materially adversely affected, and our business could be harmed
6. 33We may be subject to claims challenging the inventorship or ownership of our patents and other intellectual property, which could have a material adverse effect on our business
7. 34We may not be able to protect and enforce our trademarks and trade names or build name recognition in our markets of interest thereby harming our competitive position, which could have a material adverse effect on our business
8. 35Patent terms may be inadequate to protect our competitive position of our products for an adequate amount of time and may adversely affect our business
9. 36If we cannot license rights to use technologies on reasonable terms, we may not be able to commercialize new products in the futured and thus materially harm our business
10. 37which could have a material adverse effect on our business
11. 38The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations and may not adequately protect our business or permit us to maintain our competitive advantage

Risks Related to Regulatory and Legal Compliance Matters

1. 39We expect to incur substantial expenses in our pursuit of regulatory clearances and approvals for our products in the United States and can provide no assurances that we will obtain the necessary approvals from the FDA to market our products in the United States
2. 40We may be subject to enforcement action if we engage in improper or off-label marketing or promotion of our products, including significant legal liability, fines, penalties, and injunctions, which could materially and adversely affect our business, financial condition, and results of operations
3. 41Our business could be negatively impacted by changes in the United States political environment
4. 42Adverse findings in post-marketing vigilance or regulatory audits could subject us to suspension or withdrawal of our certificates of conformity, mandatory product recalls and significant legal liability, which could materially and adversely affect our business, financial condition, and results of operations
5. 43Our employees, independent contractors, consultants, commercial partners, distributors and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements

Risks Related to Litigation and Regulation

1. 44We are subject to risks relating to disputes and other legal proceedings, product liability lawsuits, that may be time consuming and costly

Risks Related to Financing Transactions

1. 45We are subject to financing risks. There are no guarantees that we can meet our financing needs for our operations and future investments at a reasonable cost or at all
2. 46There are risks associated with our convertible notes that could adversely affect our business and financial condition
3. 47We are subject to risks relating to increased interest rates and any adverse developments in the credit markets

Risks Related to Tax

1. 48Our ability to use net operating loss (“NOL”) carryforwards and other tax attributes may be limited as a result of the Business Combination or other ownership changes
2. 49A new 1% U.S. federal excise tax could be imposed on us in connection with redemptions by us of our stock
3. 50The excise tax is imposed on the repurchasing corporation itself, not its stockholders from which shares are repurchased
4. 51Unanticipated tax laws or any changes in tax rates or in the application of the existing tax laws to us may adversely impact our results of operations

Risks Related to Ownership of Our Securities

1. 52The Perceptive PIPE Investor has control over key decision making as a result of its control of a majority of the voting power of our outstanding common stock
2. 53We may use our financial resources in ways with which you do not agree and in ways that may not yield a favorable return
3. 54Our stock price may be volatile and may decline regardless of its operating performance
4. 55We may be unable to maintain the listing of our securities on Nasdaq in the future
5. 56An active trading market for our common stock may not be sustained
6. 57Future sales of shares by existing stockholders could cause our stock price to decline
7. 58We may issue additional shares of common stock or other equity securities without your approval, which would dilute your ownership interests and may depress the market price of the common stock
8. 59If securities or industry analysts either do not publish research about us or publish inaccurate or unfavorable research about us, our business, or its market, or if they change their recommendations regarding common stock adversely, the trading price or trading volume of the common stock could decline
9. 60Our Charter and Bylaws contain provisions that could depress the trading price of common stock by acting to discourage, delay, or prevent a change of control of us or changes in our management that our stockholders may deem advantageous
10. 61Our Charter provides that the Court of Chancery of the State of Delaware will be the exclusive forum for substantially all disputes between us and our stockholders, which could limit our stockholders’ ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees
11. 62We do not intend to pay dividends for the foreseeable future
12. 63We will incur increased costs and obligations as a result of being a public company
13. 64to attract and retain qualified board members
14. 65If we fail to establish and maintain proper and effective internal control over financial reporting, as a public company, our ability to produce accurate and timely financial statements could be impaired, investors may lose confidence in our financial reporting and the trading price of the common stock may decline
15. 66We may become subject to securities or class action litigation, which is expensive and could divert management’s attention
16. 67If securities or industry analysts do not publish research or reports about our business or publish negative reports, the market price of our common stock could decline
17. 68Changes in laws or regulations or how such laws or regulations are interpreted or applied, or a failure to comply with any laws or regulations, may adversely affect our business and results of operations